Health & Environment
Trump Administration Advances Policy For Peptides Favored By RFK Jr.
The Hindu1h
THE BRIEF
1
U.S. health officials submitted an interim access policy to the White House to allow specialty compounding pharmacies to produce certain largely unregulated peptide injections.
2
The plan aims to give compounding pharmacies enforcement discretion so they can produce popular peptides like BPC-157 without being targeted by FDA regulations.
3
The FDA previously classified BPC-157 as too risky due to potential contamination and tumor growth, going against outside advisers who recommended dropping restrictions.